GlobeNewswire Inc | Jun 29, 2021 04:01AM EDT

June 29, 2021



Sanofi launchesdedicated vaccines mRNA Center of Excellence

-- Approximately 400million investment annually to accelerate end-to-end R&D of next-generation vaccines, fully financed through resource reallocation -- Focus on innovating mRNA vaccines beyond pandemic to routine use in diseases with high unmet need -- Expected minimum of six clinical candidates by 2025

PARIS June 29, 2021 - Sanofi will invest approximately 400 million annually in a first-of-its kind vaccines mRNA Center of Excellence. The Center will work to accelerate the development and delivery of next-generation vaccines by bringing together approximately 400 dedicated employees integrating end-to-end mRNA vaccine capabilities with dedicated R&D, digital, and chemistry, manufacturing and controls (CMC) teams across sites at Cambridge, MA (US) and Marcy lEtoile, Lyon (France).

During the COVID-19 pandemic, mRNA technologies demonstrated potential to delivernew vaccines faster than ever before.However, key areas of innovation such as thermostability and tolerability improvements will be critical to unlock the applications of mRNA in routine vaccination against abroaderset of infectious diseases and across all ages.The Sanofi mRNA vaccines Centerof Excellence aims to lead the field in this next chapter of vaccine innovation, said Jean-Francois Toussaint, Global Head of Research and Development, Sanofi Pasteur.

The Center of Excellence will enable acceleration of the vaccines mRNA portfolio developed through the Translate Bio collaboration established in 2018 and expanded in 2020.

This massive new investment clearly puts us in the race to develop next-generation vaccines where mRNA technologies can have greatest impact. said Thomas Triomphe, Executive Vice President, Global Head of Sanofi Pasteur. While mRNA wont be the solution for every infectious disease, its translation into routine prevention could have immense impact for many unmet public health needs. It now becomes a critical new technology in our comprehensive vaccinestoolbox, one which could help reinvent health protection in the future.

Sanofi is committed to rapidly establishing an industry-competitive mRNA platform and is working with our partners and all relevant stakeholders, internally and externally, to achieve this objective.



About Sanofi

Sanofi is dedicated to supporting people through their health challenges. Weare a global biopharmaceutical company focused on human health. We preventillness with vaccines, provide innovative treatments to fight pain and easesuffering. We stand by the few who suffer from rare diseases and the millionswith long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transformingscientific innovation into healthcare solutions around the globe.



Investor Relations Contacts Paris Eva Schaefer-Jansen Arnaud DelepineMedia Relations Contacts Nathalie PhamAshleigh KossTel: +1 (908) 205-2572 ashleigh.koss@sanofi.com Investor Relations Contacts North America Felix Lauscher Fara BerkowitzSandrine Guendoul Suzanne GrecoTel.: +33 (0)6 25 09 14 25sandrine.guendoul@sanofi.com

IR main line: Tel.: +33 (0)1 53 77 45 45 investor.relations@sanofi.com https://www.sanofi.com/en/investors/contact

Sanofi Forward-Looking StatementsThis press release contains forward-looking statements as defined in thePrivate Securities Litigation Reform Act of 1995, as amended. Forward-lookingstatements are statements that are not historical facts. These statementsinclude projections and estimates and their underlying assumptions, statementsregarding plans, objectives, intentions and expectations with respect to futurefinancial results, events, operations, services, product development andpotential, and statements regarding future performance. Forward-lookingstatements are generally identified by the words ?expects?, ?anticipates?,?believes?, ?intends?, ?estimates?, ?plans? and similar expressions. AlthoughSanofi?s management believes that the expectations reflected in suchforward-looking statements are reasonable, investors are cautioned thatforward-looking information and statements are subject to various risks anduncertainties, many of which are difficult to predict and generally beyond thecontrol of Sanofi, that could cause actual results and developments to differmaterially from those expressed in, or implied or projected by, theforward-looking information and statements. These risks and uncertaintiesinclude among other things, the uncertainties inherent in research anddevelopment, future clinical data and analysis, including post marketing,decisions by regulatory authorities, such as the FDA or the EMA, regardingwhether and when to approve any drug, device or biological application that maybe filed for any such product candidates as well as their decisions regardinglabelling and other matters that could affect the availability or commercialpotential of such product candidates, the fact that product candidates ifapproved may not be commercially successful, the future approval and commercialsuccess of therapeutic alternatives, Sanofi?s ability to benefit from externalgrowth opportunities, to complete related transactions and/or obtain regulatoryclearances, risks associated with intellectual property and any related pendingor future litigation and the ultimate outcome of such litigation, trends inexchange rates and prevailing interest rates, volatile economic and marketconditions, cost containment initiatives and subsequent changes thereto, andthe impact that COVID-19 will have on us, our customers, suppliers, vendors,and other business partners, and the financial condition of any one of them, aswell as on our employees and on the global economy as a whole. Any materialeffect of COVID-19 on any of the foregoing could also adversely impact us. Thissituation is changing rapidly and additional impacts may arise of which we arenot currently aware and may exacerbate other previously identified risks. Therisks and uncertainties also include the uncertainties discussed or identifiedin the public filings with the SEC and the AMF made by Sanofi, including thoselisted under ?Risk Factors? and ?Cautionary Statement Regarding Forward-LookingStatements? in Sanofi?s annual report on Form 20-F for the year ended December31, 2020. Other than as required by applicable law, Sanofi does not undertakeany obligation to update or revise any forward-looking information orstatements.



Attachment

-- 21-06-29_mRNA_PR_EN